Xenetic Biosciences Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform July 29, 2025
Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance July 29, 2025
Akari Therapeutics Continues Key Research on its Novel ADC Payload PH1 to Demonstrate its Ability to Target Cancers Fueled by Oncogenic Drivers July 29, 2025
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib July 23, 2025
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML July 23, 2025
CoRegen announced the close of a $93,390,000 million financing to advance CMC development July 15, 2025
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for First-in-Class CD38×BCMA×CD3 Trispecific Antibody ISB 2001 July 15, 2025
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies July 15, 2025
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development July 15, 2025
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach July 8, 2025
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies July 8, 2025
Revolution Medicines and Summit Therapeutics to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors July 1, 2025
Sanofi to advance Kymera’s next-gen oral IRAK4 degrader KT-485 into clinical testing and will not advance KT-474 July 1, 2025
Hummingbird Bioscience Licenses HMBD-002, Ph 2-Ready Anti-VISTA Monoclonal Antibody, to Percheron Therapeutics July 1, 2025
